UY36530A - Métodos para purificar cannabinoides, composiciones y kits de estos - Google Patents

Métodos para purificar cannabinoides, composiciones y kits de estos

Info

Publication number
UY36530A
UY36530A UY0001036530A UY36530A UY36530A UY 36530 A UY36530 A UY 36530A UY 0001036530 A UY0001036530 A UY 0001036530A UY 36530 A UY36530 A UY 36530A UY 36530 A UY36530 A UY 36530A
Authority
UY
Uruguay
Prior art keywords
methods
cannabinoids
compositions
kits
purify
Prior art date
Application number
UY0001036530A
Other languages
English (en)
Inventor
Xavier Nadal Roura
Original Assignee
Phytoplant Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phytoplant Res S L filed Critical Phytoplant Res S L
Priority to UY0001039011A priority Critical patent/UY39011A/es
Publication of UY36530A publication Critical patent/UY36530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/685—Processes comprising at least two steps in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
    • C07C37/84—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
    • C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Abstract

La presente memoria descriptiva describe métodos para purificar uno o más cannabinoides de un material vegetal, cannabinoides purificados y composiciones farmacéuticas que comprenden uno o más cannabinoides producidos mediante los métodos descritos, métodos y usos para tratar una enfermedad o afección utilizando dichos cannabinoides purificados y composiciones farmacéuticas.
UY0001036530A 2015-01-22 2016-01-22 Métodos para purificar cannabinoides, composiciones y kits de estos UY36530A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY0001039011A UY39011A (es) 2015-01-22 2016-01-22 Métodos para purificar cannabinoides, composiciones y kits de estos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106644P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
UY36530A true UY36530A (es) 2016-08-31

Family

ID=55349794

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001039011A UY39011A (es) 2015-01-22 2016-01-22 Métodos para purificar cannabinoides, composiciones y kits de estos
UY0001036530A UY36530A (es) 2015-01-22 2016-01-22 Métodos para purificar cannabinoides, composiciones y kits de estos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001039011A UY39011A (es) 2015-01-22 2016-01-22 Métodos para purificar cannabinoides, composiciones y kits de estos

Country Status (21)

Country Link
US (1) US9765000B2 (es)
EP (2) EP3247371B1 (es)
JP (1) JP6342587B2 (es)
CN (2) CN110563574A (es)
AU (2) AU2016210070B2 (es)
BR (2) BR112017015536B1 (es)
CA (1) CA2977421C (es)
CL (1) CL2017001873A1 (es)
CO (1) CO2017008437A2 (es)
CY (1) CY1122994T1 (es)
DK (1) DK3247371T3 (es)
ES (1) ES2801005T3 (es)
HK (1) HK1246663A1 (es)
IL (1) IL253576B (es)
MX (1) MX364559B (es)
NZ (1) NZ734714A (es)
PE (2) PE20171108A1 (es)
PT (1) PT3247371T (es)
SI (1) SI3247371T1 (es)
UY (2) UY39011A (es)
WO (1) WO2016116628A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
BG112018A (bg) * 2015-05-22 2016-11-30 "Побелч-Гле" Оод Метод за получаване на канабиноиден извлек от коноп
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20190374502A1 (en) * 2017-02-09 2019-12-12 Bodhi Research & Development Inc. Cannabinoid-Containing Fatty Acid Formulations for Treating Disorders of the Nervous System
WO2018165740A1 (en) * 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
US10238600B2 (en) * 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
EP3641726A1 (en) 2017-06-23 2020-04-29 MedCan Pharma A/S Cannabinoid pouch
IT201700085508A1 (it) * 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
US10814338B2 (en) 2017-08-09 2020-10-27 Delta Separations, Llc Device, system and methods for separation and purification of organic compounds from botanical material
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors
EP3449992A1 (en) * 2017-09-04 2019-03-06 Bionorica Ethics GmbH Recovery of acidic cannabinoids from plant material
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
EP3703838A4 (en) * 2017-10-30 2021-08-25 Whistler Technologies Corp. TERPE ENRICHMENT METHODS AND SYSTEMS
US10941102B2 (en) * 2017-11-29 2021-03-09 Robert Henry Wohleb Aqueous leaching method to produce microcrystalline powder
US20190192429A1 (en) * 2017-12-27 2019-06-27 CannScience Innovations Inc. Sublingual formulations comprising cannabis resin, methods for making same and uses thereof
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
MX2020007960A (es) 2018-01-29 2020-09-24 Phytoplant Res S L Metodos para purificar cannabinoides usando cromatografia liquido-liquido.
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US10463986B2 (en) 2018-02-07 2019-11-05 Metagreen Ventures Extraction of organic products from plant and animal materials
EP3755318B1 (en) * 2018-02-20 2022-08-24 MyMD Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
CA3091719A1 (en) * 2018-08-08 2020-02-13 Neptune Wellness Solutions Inc. Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
MX2021004428A (es) 2018-10-18 2021-09-10 Taba Ip Llc Purificacion de cannabinoides a partir de aceite de cannabis sin purificar.
US10610805B1 (en) * 2018-12-10 2020-04-07 Natural Extraction Systems, LLC Methods to separate cannabidiol and tetrahydrocannabinol
EP3894036A2 (en) * 2018-12-11 2021-10-20 NATURALIA INGREDIENTS S.r.l Extraction method and composition obtained therefrom
CN109942380B (zh) * 2018-12-14 2022-03-22 云南芙雅生物科技有限公司 一种利用高速逆流色谱分离纯化制备大麻二酚的方法
CN113557001B (zh) * 2019-01-07 2023-10-20 卢克斯坎创新私人有限责任公司 用于将粉末状、液体状、糊状、包封的或颗粒状活性成分组合物压片的装置
WO2020180759A1 (en) * 2019-03-02 2020-09-10 Martha Knight Cannabinoid separation by countercurrent chromatography
CN110304993A (zh) * 2019-05-23 2019-10-08 朱法科 色谱生产高纯度大麻二酚的方法
AU2020293031B2 (en) 2019-06-12 2022-03-31 Nectar Health Sciences Inc. Methods for extraction, processing, and purification of a selected family of target compounds from cannabis
WO2020252369A1 (en) * 2019-06-14 2020-12-17 Purisys Llc Crystalline cannabigerol
CN110283048B (zh) * 2019-06-28 2020-09-11 云南翰谷生物科技有限公司 大麻二酚晶体的制备方法
WO2021012044A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
WO2021012047A1 (en) * 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a tubular flow reactor
WO2021037343A1 (en) * 2019-08-27 2021-03-04 Herbolea Biotech S.R.L. Cannabinoid concentrate and isolate, method of obtaining the same and use thereof
CA3150266A1 (en) * 2019-09-06 2021-03-11 Joanne Holland CANNABIGEROL-PROLINE CO-CRYSTALS
CN110590511B (zh) * 2019-09-11 2021-05-28 上海同田生物技术股份有限公司 一种同时分离次大麻二酚和大麻萜酚的方法
US20230346807A1 (en) * 2020-01-16 2023-11-02 Caldera Group Llc Methods for producing cannabinoid-containing crystals using supercritical fluid
WO2021195540A1 (en) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Cannabinoid based composition for mitigation of viral effects
US20210402325A1 (en) * 2020-06-26 2021-12-30 John Naito Cannabinoid crystallization methods and systems
AR123595A1 (es) 2020-09-25 2022-12-21 Medpharm Iowa Llc Proceso de extracción piggyback para cannabinoides y métodos relacionados
CN112279752B (zh) * 2020-10-30 2022-11-11 云南芙雅生物科技有限公司 用于工业大麻的大麻素二氧化碳超临界提取方法
US11433319B1 (en) 2021-02-12 2022-09-06 Rocky Mountain Extraction Services, LLC Systems and methods for organic isolation of target compounds from source materials
WO2022182844A1 (en) * 2021-02-24 2022-09-01 Molecular Infusions Llc Purified cannabinodis isolated from fermentate
WO2022192793A1 (en) * 2021-03-12 2022-09-15 Treehouse Biosciences, Inc. Solvent limited isolation of crystalline cannabinoids
USD1011476S1 (en) 2023-10-27 2024-01-16 Aether Green, LLC Filter spacer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
NZ552547A (en) * 2002-02-01 2008-03-28 Resolution Chemicals Ltd Production of Delta 9 tetrahydrocannabinol from plant material
DK2311475T3 (en) * 2002-08-14 2016-09-19 Gw Pharma Ltd Extraction of pharmaceutically active cannabinoids FROM PLANT MATERIALS
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
WO2006007734A1 (de) * 2004-07-19 2006-01-26 Cilag Ltd. Verfahren zur gewinnung von reinem tetrahydrocannabinol
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
ES2806034T3 (es) * 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones

Also Published As

Publication number Publication date
CN107567435B (zh) 2019-08-09
EP3247371B1 (en) 2020-04-01
PT3247371T (pt) 2020-07-02
SI3247371T1 (sl) 2020-08-31
CN110563574A (zh) 2019-12-13
CY1122994T1 (el) 2021-10-29
AU2021203749A1 (en) 2021-07-08
BR122019001241B1 (pt) 2021-05-04
CA2977421C (en) 2022-10-18
CN107567435A (zh) 2018-01-09
AU2016210070A1 (en) 2017-09-07
US20160214920A1 (en) 2016-07-28
MX364559B (es) 2019-04-30
CL2017001873A1 (es) 2018-04-13
WO2016116628A1 (en) 2016-07-28
HK1246663A1 (zh) 2018-09-14
PE20211694A1 (es) 2021-09-01
UY39011A (es) 2021-02-26
ES2801005T3 (es) 2021-01-07
EP3556376A1 (en) 2019-10-23
EP3247371A1 (en) 2017-11-29
AU2016210070B2 (en) 2021-10-28
CO2017008437A2 (es) 2018-01-05
AU2021203749B2 (en) 2022-02-03
BR112017015536A2 (pt) 2018-04-17
JP6342587B2 (ja) 2018-06-13
US9765000B2 (en) 2017-09-19
IL253576B (en) 2018-11-29
MX2017009561A (es) 2018-06-20
NZ734714A (en) 2023-07-28
CA2977421A1 (en) 2016-07-28
PE20171108A1 (es) 2017-08-07
JP2018504407A (ja) 2018-02-15
BR112017015536B1 (pt) 2021-05-18
DK3247371T3 (da) 2020-06-15
IL253576A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
UY36530A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
CL2017002650A1 (es) Compuestos novedosos
CO2021005987A2 (es) Compuestos de anillo fusionado
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018002794A1 (es) Compuestos bicíclicos
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
DOP2016000253A (es) Nuevos compuestos
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CO2017010720A2 (es) Proceso para aislar y purificar ambrox
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210706